Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arlene Chan

Showing results (31-40 of 86) with videos related to

Pageof 9
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 11, 2017
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study)Arlene Chan, R De Boer, A Gan, et al.
Asia-Pacific Journal of Clinical Oncology|September 12, 2019
Compliance with multidisciplinary team meeting management recommendationsAmali Samarasinghe, Arlene Chan, Diana Hastrich, et al.
Asia-Pacific Journal of Clinical Oncology|October 30, 2014
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancerArlene Chan, Catherine Shannon, Richard de Boer, et al.
The Medical Journal of Australia|September 23, 2009
A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western AustraliaChristobel M Saunders, Gudrun Peters, Glenys Longman, et al.
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Anticancer Research|June 11, 2013
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancerArlene Chan, Pier-Franco Conte, Lubos Petruzelka, et al.
Clinical Breast Cancer|October 21, 2016
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast CancerSaverio Cinieri, Arlene Chan, Kadri Altundag, et al.
Breast Cancer Research and Treatment|August 9, 2012
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancerRichard H De Boer, Dusan Kotasek, Shane White, et al.
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancerArlene Chan, Peter C Willsher, Diana J Hastrich, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Pageof 9

Showing results (31-40 of 86) with videos related to

Sort By:
Pageof 9
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 11, 2017
Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study)Arlene Chan, R De Boer, A Gan, et al.
Asia-Pacific Journal of Clinical Oncology|September 12, 2019
Compliance with multidisciplinary team meeting management recommendationsAmali Samarasinghe, Arlene Chan, Diana Hastrich, et al.
Asia-Pacific Journal of Clinical Oncology|October 30, 2014
Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancerArlene Chan, Catherine Shannon, Richard de Boer, et al.
The Medical Journal of Australia|September 23, 2009
A pilot study of trimodality breast imaging surveillance in young women at high risk of breast cancer in Western AustraliaChristobel M Saunders, Gudrun Peters, Glenys Longman, et al.
Future Oncology (London, England)|December 29, 2025
OPERA-01: a phase III study of palazestrant for ER+, HER2- advanced breast cancer after CDK4/6 inhibitor therapyBarbara Pistilli, Meritxell Bellet Ezquerra, Lucia Del Mastro, et al.
Anticancer Research|June 11, 2013
Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancerArlene Chan, Pier-Franco Conte, Lubos Petruzelka, et al.
Clinical Breast Cancer|October 21, 2016
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast CancerSaverio Cinieri, Arlene Chan, Kadri Altundag, et al.
Breast Cancer Research and Treatment|August 9, 2012
Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancerRichard H De Boer, Dusan Kotasek, Shane White, et al.
Asia-Pacific Journal of Clinical Oncology|February 29, 2012
Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancerArlene Chan, Peter C Willsher, Diana J Hastrich, et al.
Breast Cancer Research : BCR|September 26, 2013
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancerRebecca A Dent, Geoffrey J Lindeman, Mark Clemons, et al.
Pageof 9